Grand Pharma’s subsidiary Grand Pharm (China) Company Limited (湖北远大富源生 命科技有限公司) has entered into a share purchase agreement to acquire all equity of Hebei Yuanda Jiufu Biotechnology Co., Ltd. (河北远大九孚生物科技有限公司) and Baoding Jiahe Fine Chemical Co., Ltd. (保定加合精细化工有限公司). The Transaction will comprehensively strengthen Grand Pharma’s integrated industrial chain layout in the biotechnology sector. Upon completion of the Share Purchase Agreement, the Target Companies will become indirectly wholly-owned subsidiaries of the Company.

• The Target Companies are biomanufacturing enterprises with a longstanding commitment to researching, developing and applying fermentation engineering and enzyme engineering technologies to replace traditional chemical synthesis methods for producing various edible amino acids.
• The Transaction represents a significant strategic initiative by the Group to implement its core operational philosophy of ‘New Technologies, High Quality, Industrial Chain Integration, and Internationalisation’, establishing multiple core advantages through industrial chain synergy.
• Grand Pharma has been deeply engaged in the amino acid field for more than 20 years. Driven by scientific and technological innovation, we have made synthetic biology its core focus. It was the first in China to develop globally leading bio-based production technologies. Through these technologies, we produce a wide range of amino acids and addresses critical gaps in the industry.